MoonLake Immunotherapeutics — Q2 2022 Form 10-Q
Business context and reporting period
Clinical-stage biotechnology company developing sonelokimab (SLK), an IL-17A/IL-17F inhibitor, for inflammatory diseases. This unaudited report covers the quarter and six months ended June 30, 2022; 2021 comparative results were restated. The April 5, 2022 business combination with Helix was accounted for as a reverse recapitalization. The company has no approved products and has generated no product revenue.
Financial performance and position
- Revenue: None.
- Q2 2022: R&D expense was $11.4 million and G&A expense was $6.3 million; total operating expenses and operating loss were $17.7 million. Net loss was $17.4 million, including $5.3 million attributable to noncontrolling interests. Loss attributable to controlling shareholders was $12.1 million, or $0.34 per Class A share.
- First half 2022: Operating expenses were $33.6 million and net loss was $33.3 million. Net loss attributable to controlling shareholders was $22.8 million, or $1.13 per Class A share.
- Cash flow: Operating cash use was $34.9 million for the first half; investing cash use was $16,000. Financing provided $119.7 million, primarily from the business combination, net of a $15.0 million loan repayment. Cash increased by $84.7 million.
- Liquidity and debt: June 30 cash was $92.7 million; current assets were $98.4 million versus current liabilities of $3.9 million. The $15.0 million short-term loan outstanding at year-end was repaid; no short-term loan remained at June 30. Management estimated available funds would support operations into the second half of 2024.
- Margins: Not meaningful because the company had no revenue. The company expects significant operating losses as it advances development.
Material changes versus prior comparable periods
- Q2 R&D expense fell $18.5 million year over year, largely because the prior-year quarter included a one-time $25.0 million SLK license/IPR&D charge. 2022 R&D included a $5.4 million license milestone and costs for Phase 2 trials begun in April.
- Q2 G&A rose $3.4 million year over year, reflecting increased share-based compensation, personnel, insurance, and public-company legal and professional costs.
- First-half net loss was broadly similar to the restated prior-year period ($33.3 million versus $33.0 million), as lower R&D was largely offset by higher G&A.
- The business combination generated $134.7 million of net proceeds. At June 30, 36.9 million Class A and 15.8 million Class C shares were outstanding; Class C shares carry voting rights but no economic rights.
Outlook, risks, contingencies, and unusual items
- Management expects to start Phase 2 PsA trials in the United States and Europe in the second half of 2022. Phase 2 HS trials began in April 2022. Management expects spending and losses to rise with clinical development and states that substantial additional funding will eventually be needed.
- Contractual obligations totaled $44.8 million, including $44.4 million in purchase obligations, mostly for clinical research and manufacturing. Separately, the SLK license includes potential milestone payments of up to €302.1 million ($315.3 million at the June 30 exchange rate) and royalties in the low-to-mid-teen percentage range on net sales.
- Key risks include clinical and regulatory uncertainty, dependence on SLK, need for future capital, third-party manufacturing and research reliance, and potential COVID-19-related disruption. Management said COVID-19’s impact to date had been limited, but future effects remain uncertain.
- The filing reports that disclosure controls were not effective as of June 30 due to an unremediated material weakness in review controls for complex, bespoke transactions. Remediation measures were underway but had not operated long enough to be considered effective.
- 2021 results were restated to record compensation expense for restricted founder shares; the restatement increased prior-period G&A and losses. No material legal proceedings were reported.
Important facts for investors to verify
- Whether clinical trial progress, enrollment, safety, and efficacy support the planned SLK development timetable.
- Whether the stated cash runway into the second half of 2024 remains achievable as trial and manufacturing costs develop.
- The timing and likelihood of license milestones, and the effect of contractual commitments and potential future financing on cash and dilution.
- Whether management’s remediation of the material weakness is completed and tested as effective.
- Share-class conversion and ownership mechanics, including the economic interests represented by Class C shares and noncontrolling interests.